

Partner, New York

Antitrust/Competition



T: 212.735.2425
maria.raptis@skadden.com

Education

J.D., Columbia Law School, 2002

B.A., Columbia College, 1998

Bar Admissions

New York

Maria A. Raptis represents clients in connection with antitrust aspects of mergers and acquisitions, litigation, counseling and criminal matters.

Ms. Raptis concentrates her practice on representing clients before the Federal Trade Commission (FTC) and Department of Justice. She has advised clients in a broad range of strategic transactions across multiple industries, including health care and pharmaceuticals, technology, consumer products, entertainment and manufacturing. Ms. Raptis has been named to *Chambers USA*, in which clients say she is a “great business partner, incredibly responsive and highly in-tune to the general market.” She also has been named among North America’s Top Antitrust Lawyers and Top Female M&A Lawyers by *MergerLinks*, as well as Lawdragon’s 500 Leading Lawyers in America. Additionally, she has been recognized by *Who’s Who Legal: Competition*. Some of her significant representations include:

- **Activision Blizzard Inc.** in its \$75 billion acquisition by Microsoft Corporation, the largest-ever technology deal and the largest-ever gaming industry deal
- **Xilinx, Inc.** in its \$50 billion acquisition by Advanced Micro Devices, Inc.
- **Livongo Health** in its \$18.5 billion sale to Teladoc
- **Visa Inc.** in its proposed but terminated \$5.3 billion acquisition of Plaid Inc., its \$2.2 billion acquisition of Tink AB and its \$1 billion acquisition of Pismo
- **Actavis** in its \$28 billion acquisition of Forest Laboratories and its \$8.5 billion acquisition of Warner Chilcott
- **Array BioPharma** in its \$11.4 billion acquisition by Pfizer
- **Gilead Sciences, Inc.** in its \$4.9 billion acquisition of Forty Seven, its \$5.1 billion 10-year global research and development collaboration and equity investment in Galapagos NV, its \$11.9 billion acquisition of Kite Pharma, Inc., its \$11 billion acquisition of Pharmasset and its acquisition of Cell Design Labs for up to \$567 million
- **Juno Therapeutics, Inc.** in its \$11 billion acquisition by Celgene Corporation
- **Iveric Bio** in its \$5.9 billion sale to Astellas
- **Dicerna Pharmaceuticals** in its \$3.3 billion sale to Novo Nordisk
- **BELLUS Health** in its \$2 billion sale to GSK
- **ZeniMax Media Inc.** in its \$7.5 billion acquisition by Microsoft Corporation
- **PayPal** in its \$4 billion acquisition of Honey Science Corporation and its strategic investments in MercadoLibre, Inc. and Uber Technologies, Inc.
- **Entegris** in its \$6.5 billion cash and stock acquisition of CMC Materials and the pending sale of its electronic chemicals business to Fujifilm for \$700 million
- **Pandion Therapeutics** in its sale to Merck for \$1.8 billion
- **CTI BioPharma** in its \$1.7 billion sale to Swedish Orphan Biovitrum (SOBI)
- **MorphoSys** in its \$1.7 billion acquisition of Constellation Pharmaceuticals and its related financing from Royalty Pharma totaling over \$2 billion

Maria Raptis

Continued

-
- **Achillion Pharmaceuticals, Inc.** in its \$930 million acquisition by Alexion Pharmaceuticals, Inc.
 - **Alcon** in its \$753 million acquisition of Aerie Pharmaceuticals
 - **Mayne Pharma Group Limited** in its \$475 million sale of Metrics Contracts Services to Catalent, Inc.
 - **Vertex Pharmaceuticals** in its \$320 million acquisition of ViaCyte
 - **NXP Semiconductors N.V.** in its proposed but terminated \$47 billion acquisition by Qualcomm Incorporated
 - **Intel Corporation** in numerous transactions, including its \$15.3 billion acquisition of Mobileye N.V., its \$1 billion sale of its modem business to Apple and its proposed but terminated \$5.4 billion acquisition of Tower Semiconductor
 - **Hewlett Packard Enterprise Co.** in its \$1.3 billion acquisition of Cray Inc. and its \$1 billion acquisition of Samsung's printing business
 - **First Bancorp.** in its \$1.1 billion acquisition of Banco Santander S.A.'s (Spain) Puerto Rico banking operations
 - **Cineworld Group PLC** in its \$5.9 billion acquisition of Regal Entertainment Group
 - **Ionis Pharmaceuticals** in its acquisition of the remaining outstanding stake of Akcea Therapeutics for \$500 million
 - **Airbnb** in its \$400 million acquisition of Hotel Tonight
 - **Carbonite, Inc.** in its \$1.4 billion acquisition by Open Text Corporation
 - **Sophos Group plc** with U.S. aspects of its \$3.9 billion acquisition by Thoma Bravo, LLC
 - **ArQule** in its sale to Merck for \$2.7 billion
 - **Alder BioPharmaceuticals** in its sale to Lundbeck for up to \$1.95 billion
 - **CerSci Therapeutics** in its sale to ACADIA Pharmaceuticals for up to \$939.5 million
 - **Stemline Therapeutics** in its sale to Menarini Group for up to \$677 million
 - **TiVo Inc.** in its \$1.1 billion acquisition by Rovi Corporation
 - **SanDisk** in its \$19 billion acquisition by Western Digital
 - **Valeant** in its acquisitions of Salix, Medicis, Dermik, Ortho Dermatologics and Biovail
 - **Watson** in its \$5.9 billion acquisition of Actavis and its \$1.9 billion acquisition of Andrx
 - **NDS Group** in its \$5 billion acquisition by Cisco Systems
- Ms. Raptis' recent litigation experience includes defending Activision in a challenge by the FTC to its acquisition by Microsoft. She also has represented clients in connection with class actions and multidistrict litigations challenging patent settlements, pricing and other business policies, including Actavis in suits brought by the FTC and private plaintiffs relating to "reverse payment" settlements and De Beers in connection with national class actions involving gem diamonds.
- Ms. Raptis also has represented clients in connection with allegations of price-fixing and other criminal charges, including De Beers in connection with the resolution of a criminal matter relating to industrial diamonds.